{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.58","upperLimit":"96.86","value":"95.22"},{"groupId":"OG001","lowerLimit":"84.56","upperLimit":"92.48","value":"88.52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"926"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"description":"Event-free probability where EFS is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.\n\ndoxorubicin hydrochloride: Given IV or IT\n\ncytarabine: Given IV or SC\n\ndexamethasone: Given IV or PO\n\npegaspargase: Given IM\n\nmethotrexate: Given IM or IT\n\nleucovorin calcium: Given PO\n\nmercaptopurine: Given PO\n\ncyclophosphamide: Given IV\n\nthioguanine: Given PO\n\nvincristine sulfate: Given IV","id":"OG000","title":"Group 1-SR-low ALL, Arm I-combination Chemotherapy"},{"description":"Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.\n\ndoxorubicin hydrochloride: Given IV or IT\n\ncytarabine: Given IV or SC\n\ndexamethasone: Given IV or PO\n\npegaspargase: Given IM\n\nmethotrexate: Given IM or IT\n\nleucovorin calcium: Given PO\n\nmercaptopurine: Given PO\n\ncyclophosphamide: Given IV\n\nthioguanine: Given PO\n\nvincristine sulfate: Given IV","id":"OG001","title":"Group 2-SR-avg ALL, Arm I-combination Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Patients on the two arms being compared got similar therapy. All patients included in this analysis are MRD negative. SR-Average patients who were CNS2 at diagnosis were excluded in order to have comparable patient cohorts. SR-Low patients are TEL/Trisomy positive while SR-Average patients are TEL/Trisomy negative.","reportingStatus":"POSTED","timeFrame":"6 years","title":"Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)","type":"SECONDARY","unitOfMeasure":"Percent probability"}